登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>LY75 >LY5-H52H3

Human LY75 / CD205 Protein, His Tag

分子别名(Synonym)

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

表达区间及表达系统(Source)

Human LY75, His Tag (LY5-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ser 28 - Asp 1666 (Accession # O60449-1).

Predicted N-terminus: Ser 28

Request for sequence

蛋白结构(Molecular Characterization)

Online(Ser 28 - Asp 1666) O60449-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 190.7 kDa. The protein migrates as 200-230 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Human LY75, His Tag (Cat. No. LY5-H52H3) SDS-PAGE gel

Human LY75, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

背景(Background)

lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.

 

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
LY75靶点信息
英文全称:Lymphocyte antigen 75
中文全称:淋巴细胞抗原-75
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定